Early results from the Phase 3 PURPOSE 1 trial reveal that an injectable antiretroviral drug, administered twice a year, can effectively prevent HIV infection in cisgender women. Professor Thesla Palanee-Phillips, director of clinical trials at Wits RHI, hailed the findings as historic, saying this is the first HIV prevention trial ever to show zero HIV infections with an intervention. The…